Recommended Topic Related To:

Lucentis

"By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria—the energy factories within cells. Doctors might someday use the approach to treat a variety of mito"...

Lucentis

Lucentis

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in the WARNINGS AND PRECAUTIONS (5) section of the label:

  • Endophthalmitis and Retinal Detachments
  • Increases in Intraocular Pressure
  • Thromboembolic Events
  • Fatal Events in DME Patients

Injection Procedure

Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections, including endophthalmitis [see WARNINGS AND PRECAUTIONS], rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.

The data below reflect exposure to 0.5 mg LUCENTIS in 440 patients with neovascular AMD in Studies AMD-1, AMD-2, and AMD-3, and 259 patients with macular edema following RVO. The data also reflect exposure to 0.3 mg LUCENTIS in 250 patients with DME [see Clinical Studies].

Safety data observed in Study AMD-4 were consistent with these results. On average, the rates and types of adverse reactions in patients were not significantly affected by dosing regimen.

Ocular Reactions

Table 1 shows frequently reported ocular adverse reactions in LUCENTIS-treated patients compared with the control group.

Table 1 : Ocular Reactions in the DME, AMD, and RVO Studies

Adverse Reaction DME 2-year AMD 2-year AMD 1-year RVO 6-month
LUCENTIS 0.3 mg Control LUCENTIS 0.5 mg Control LUCENTIS 0.5 mg Control LUCENTIS 0.5 mg Control
n=250 n=250 n=379 n=379 n=440 n=441 n=259n =260
Conjunctival hemorrhage 47% 32% 74% 60% 64% 50% 48% 37%
Eye pain 17% 13% 35% 30% 26% 20% 17% 12%
Vitreous floaters 10% 4% 27% 8% 19% 5% 7% 2%
Intraocular pressure increased 18% 7% 24% 7% 17% 5% 7% 2%
Vitreous detachment 11% 15% 21% 19% 15% 15% 4% 2%
Intraocular inflammation 4% 3% 18% 8% 13% 7% 1% 3%
Cataract 28% 32% 17% 14% 11% 9% 2% 2%
Foreign body sensation in eyes 10% 5% 16% 14% 13% 10% 7% 5%
Eye irritation 8% 5% 15% 15% 13% 12% 7% 6%
Lacrimation increased 5% 4% 14% 12% 8% 8% 2% 3%
Blepharitis 3% 2% 12% 8% 8% 5% 0% 1%
Dry eye 5% 3% 12% 7% 7% 7% 3% 3%
Visual disturbance or vision blurred 8% 4% 18% 15% 13% 10% 5% 3%
Eye pruritis 4% 4% 12% 11% 9% 7% 1% 2%
Ocular hyperemia 9% 9% 11% 8% 7% 4% 5% 3%
Retinal disorder 2% 2% 10% 7% 8% 4% 2% 1%
Maculopathy 5% 7% 9% 9% 6% 6% 11% 7%
Retinal degeneration 1% 0% 8% 6% 5% 3% 1% 0%
Ocular discomfort 2% 1% 7% 4% 5% 2% 2% 2%
Conjunctival hyperemia 1% 2% 7% 6% 5% 4% 0% 0%
Posterior capsule opacification 4% 3% 7% 4% 2% 2% 0% 1%
Injection site hemorrhage 1% 0% 5% 2% 3% 1% 0% 0%

Non-Ocular Reactions

Non-ocular adverse reactions with an incidence of ≥ 5% in patients receiving LUCENTIS for DME, AMD, and/or RVO and which occurred at a ≥ 1% higher frequency in patients treated with LUCENTIS compared to control are shown in Table 2. Though less common, wound healing complications were also observed in some studies.

Table 2 : Non-Ocular Reactions in the DME, AMD and RVO Studies

Adverse Reaction DME 2-year AMD 2-year AMD 1-year RVO 6-month
LUCENTIS 0.3 mg Control LUCENTIS 0.5 mg Control LUCENTIS 0.5 mg Control LUCENTIS 0.5 mg Control
n=250 n=250 n=379 n=379 n=440 n=441 n=259 n=260
Nasopharyngitis 12% 6% 16% 13% 8% 9% 5% 4%
Anemia 11% 10% 8% 7% 4% 3% 1% 1%
Nausea 10% 9% 9% 6% 5% 5% 1% 2%
Cough 9% 4% 9% 8% 5% 4% 1% 2%
Constipation 8% 4% 5% 7% 3% 4% 0% 1%
Seasonal allergy 8% 4% 4% 4% 2% 2% 0% 2%
Hypercholesterolemia 7% 5% 5% 5% 3% 2% 1% 1%
Influenza 7% 3% 7% 5% 3% 2% 3% 2%
Renal failure 7% 6% 1% 1% 0% 0% 0% 0%
Upper respiratory tract infection 7% 7% 9% 8% 5% 5% 2% 2%
Gastroesophageal reflux disease 6% 4% 4% 6% 3% 4% 1% 0%
Headache 6% 8% 12% 9% 6% 5% 3% 3%
Edema peripheral 6% 4% 3% 5% 2% 3% 0% 1%
Renal failure chronic 6% 2% 0% 1% 0% 0% 0% 0%
Neuropathy peripheral 5% 3% 1% 1% 1% 0% 0% 0%
Sinusitis 5% 8% 8% 7% 5% 5% 3% 2%
Bronchitis 4% 4% 11% 9% 6% 5% 0% 2%
Atrial fibrillation 3% 3% 5% 4% 2% 2% 1% 0%
Arthralgia 3% 3% 11% 9% 5% 5% 2% 1%
Chronic obstructive pulmonary disease 1% 1% 6% 3% 3% 1% 0% 0%
Wound healing complications 1% 0% 1% 1% 1% 0% 0% 0%

Immunogenicity

As with all therapeutic proteins, there is the potential for an immune response in patients treated with LUCENTIS. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to LUCENTIS in immunoassays and are highly dependent on the sensitivity and specificity of the assays.

The pre-treatment incidence of immunoreactivity to LUCENTIS was 0%-5% across treatment groups. After monthly dosing with LUCENTIS for 6 to 24 months, antibodies to LUCENTIS were detected in approximately 1%-9% of patients.

The clinical significance of immunoreactivity to LUCENTIS is unclear at this time. Among neovascular AMD patients with the highest levels of immunoreactivity, some were noted to have iritis or vitritis. Intraocular inflammation was not observed in DME or RVO patients with the highest levels of immunoreactivity.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of LUCENTIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Read the Lucentis (ranibizumab injection) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Drug interaction studies have not been conducted with LUCENTIS.

LUCENTIS intravitreal injection has been used adjunctively with verteporfin photodynamic therapy (PDT). Twelve (12) of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (± 2 days) after verteporfin PDT.

Last reviewed on RxList: 3/17/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Lucentis - User Reviews

Lucentis User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Lucentis sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


WebMD Daily

Get breaking medical news.

Related Drugs
Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations